Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases

Authors: Treadway G.; Reisman A.

Source: International Journal of Antimicrobial Agents, Volume 18, Number 5, November 2001 , pp. 427-431(5)

Publisher: Elsevier

Keywords: Azithromycin; Safety; Paediatric; Macrolide; -Lactam; Infectious diseases

Language: English

Document Type: Research article

DOI: http://dx.doi.org/10.1016/S0924-8579(01)00439-3

Affiliations: 1: Pfizer Pharmaceuticals Group, Pfizer Inc., 235 East 42nd Street, 10017-5755, New York, NY, USA

Publication date: 2001-11-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Treadway G. ;  Reisman A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers